Biotech Values

[ghmm]

OMER:

I didn't find a new report just the one from the 14th. Am I missing another one somewhere?

I still have interest in OMER the criticisms I have of the company are:
1) How they respond to this and the "Art Doyle" report a while back make them look bad.
2) They do raise the issue of management (lack of) transparency and creditability though this was kinda known already.
3) The C5 space is seemingly more crowded.